Osang Healthcare Q1 2026: Operating Loss of KRW 4.4B, Continues Shareholder Returns with 200K Share Cancellation

Consolidated revenue KRW 22.9B, operating loss KRW 4.4B, net loss KRW 3.6B (vs operating profit of KRW 2.4B in Q1 2025)
Cancellation of 200,000 treasury shares on March 30, 2026 (profit cancellation)
Cash dividend of KRW 200 per share for FY2025 (payout ratio target over 25%)
Debt ratio 21.34% (up from 19.51% at end of 2025)
R&D expense KRW 6.0B, ratio to sales 26.43% (vs 15.61% in FY2025)
Revenue breakdown: biochemistry 65.08%, immunoassay 30.77%, molecular diagnostics 2.63%
Largest shareholder OSANG and related parties hold 56.97%
Equity method losses from associates (ALLEZ HEALTH, KRYPTOS) of KRW 1.66B
Forex sensitivity: 5% USD/KRW change impacts pre-tax profit by approx KRW 1.7B
Two ongoing lawsuits (damage claims), no provision recognized